Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled N-Acetylcysteine in Pulmonary Fibrosis
NCT03720483Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetylcysteine in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Forced Vital Capacity at Week 18 and Diffusing Capacity of the Lungs for Carbon Monoxide at Week 18. Planned start Jan 2022; status: withdrawn.
02
Drugs
acetylcysteine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03720483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720483.